|Bid||3.3000 x 1100|
|Ask||3.3100 x 1200|
|Day's Range||3.1804 - 3.4510|
|52 Week Range||1.6000 - 5.9700|
|Beta (5Y Monthly)||1.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) rose 8% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 62.50% year over year to ($0.09), which beat the estimate of ($0.17).Revenue of $11,246,000 higher by 110.92% year over year, which beat the estimate of $7,760,000.Guidance Earnings guidance hasn't been issued by the company for now.Pieris Pharmaceuticals hasn't issued any revenue guidance for the time being.Conference Call Details Date: Aug 10, 2020View more earnings on PIRSTime: 08:00 AMET Webcast URL: https://www.pieris.com/news-and-events/upcoming-eventsPrice Action Company's 52-week high was at $5.9752-week low: $1.60Price action over last quarter: Up 7.05%Company Overview Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of United States.See more from Benzinga * Earnings Scheduled For August 10, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
"We look forward to beginning the phase 2 trials of our lead clinical programs, PRS-343 and PRS-060, later this year.
BOSTON, MA / ACCESSWIRE / August 10, 2020 / Pieris Pharmaceuticals, Inc.